Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed)

The summary for the Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed): This administrative supplement funding opportunity announcement (FOA) from the National Cancer Institute (NCI) is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents. The DRSN was also developed to assist in issues of cancer drug resistance in the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical industry partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-U54 investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials.

Federal Grant Title:	Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-18-752
Type of Funding:	Grant
CFDA Numbers:	93.394, 93.395
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 30th, 2018
Original Application Deadline:	June 30th, 2018
Posted Date:	April 11th, 2018
Creation Date:	April 11th, 2018
Archive Date:	August 5th, 2018
Total Program Funding:	$500,000
Maximum Federal Grant Award:	$250,000
Minimum Federal Grant Award:
Expected Number of Awards:	2
Cost Sharing or Matching:	No
Last Updated:	April 11th, 2018

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-18-752.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologi...; • Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...; • Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate C...; • Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic...; • Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...; • Image-Guided Cancer Interventions (STTR [R41/R42]); • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44); • In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...